A drug called daraxonrasib nearly doubled the average survival time for people with advanced pancreatic cancer in a 500-person clinical trial, results that researchers at the American Society of Clinical Oncology’s annual meeting in Chicago are calling unprecedented for one of medicine’s most stubbornly lethal diseases.
The Numbers That Stopped the Room
Patients with metastatic pancreatic ductal adenocarcinoma who received daraxonrasib lived a median of 13.2 months, compared to 6.7 months for those on standard chemotherapy. The drug also produced fewer side effects than chemo, a combination of efficacy and tolerability that pancreatic cancer researchers have been chasing for decades. Revolution Medicines, the company behind the pill, presented the phase 3 RASolute 302 trial data at ASCO 2026, which runs through June 2 in Chicago.
To put 13.2 months in context: pancreatic cancer has a five-year survival rate of roughly 13 percent. It killed more than 50,000 Americans last year. The disease has resisted drug after drug because the RAS proteins that drive its growth were considered “undruggable” for decades. Daraxonrasib is a multi-selective RAS(ON) inhibitor, a daily pill that blocks the growth-powering proteins made by mutated RAS genes, and the ASCO data suggest the undruggable era may finally be ending.
Why This Matters Beyond Pancreatic Cancer
The implications extend far past a single tumor type. RAS mutations are present in roughly a quarter of all human cancers, including lung, colon, and ovarian tumors. NBC News reported that Revolution Medicines is already running additional clinical trials testing daraxonrasib as a first-line treatment for pancreatic cancer and as a therapy for other RAS-driven malignancies. If the drug performs similarly in those settings, it could reshape treatment protocols across oncology.
The timing is notable. ASCO 2026 has also seen promising data on a therapeutic cancer “jab” for head and neck cancers and new research linking insomnia to elevated cancer risk, according to Cancer Research UK’s ASCO roundup. But daraxonrasib’s pancreatic data is the clear headliner, both for the scale of the survival benefit and for what it signals about the broader RAS-targeting pipeline.
The Road to Approval
Revolution Medicines said it plans to submit the RASolute 302 data to the U.S. Food and Drug Administration to support assessment of daraxonrasib for approval. The regulatory timeline is uncertain, but the strength of the phase 3 results, a near-doubling of median survival in a 500-patient trial against an active comparator, should give the company a strong submission package.
The company’s stock had already been climbing on earlier trial readouts, and the ASCO presentation is likely to accelerate both investor interest and competitive pressure. Several other pharmaceutical companies are working on their own RAS inhibitors, and the daraxonrasib data will raise the bar for what “clinically meaningful” looks like in this space.
What Patients Should Know
For the roughly 64,000 Americans who will be diagnosed with pancreatic cancer this year, the ASCO data represents something that has been painfully rare in this disease: genuine progress. Daraxonrasib is not yet approved, and the 13.2-month median survival number, while transformative by pancreatic cancer standards, still underscores how lethal this cancer remains. But for a disease where the global health community has struggled to move the needle on survival for decades, doubling it with a daily pill and fewer side effects is the kind of result that changes research trajectories. The question now is whether the broader RAS-targeting revolution that daraxonrasib is leading will deliver similar results where patients need them most.